Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18333371 | 0.89 | APEX1 (0.44) | CYP3A4GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL11080013 | 0.87 | APEX1 (0.42) | CYP3A4GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL12580005 | 0.85 | CYP3A4 (0.64) | CYP3A4GAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL12580004 | 0.85 | CYP3A4 (0.64) | CYP3A4GAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL157928 | 0.83 | CYP3A4 (0.71) | CYP3A4GAANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL11077876 | 0.81 | CYP3A4 (0.68) | CYP3A4GAANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL19722545 | 0.79 | CYP3A4 (0.55) | CYP3A4GAAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL13661089 | 0.78 | CYP3A4 (0.58) | CYP3A4GAANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL24404192 | 0.78 | B3GNT2 (0.38) | GAAKMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL1560781 | 0.75 | CYP3A4 (0.54) | CYP3A4KMT2ASMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277945-B1 | CROSS-LINKABLE POLYMER COMPOSITION, AND MOLDED PRODUCT OF THE COMPOSITION | NIPPON KASEI CHEM (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-8445600-B2 | Crosslinking agent, and crosslinking polymer composition and molded product formed of the same | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| JP-2011236189-A | METHOD FOR SYNTHESIZING DISUBSTITUTED ISOCYANURIC ACID COMPOUND | MORI TAKASHI | 2011-11-24 | — | — | JP | disclosed |
| US-20110105687-A1 | CROSSLINKING AGENT, AND CROSSLINKING POLYMER COMPOSITION AND MOLDED PRODUCT FORMED OF THE SAME | SHINRYO CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2277945-A1 | CROSS-LINKING AGENT, CROSS-LINKABLE POLYMER COMPOSITION, AND MOLDED PRODUCT OF THE COMPOSITION | Nippon Kasei Chemical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105687-A1 | CROSSLINKING AGENT, AND CROSSLINKING POLYMER COMPOSITION AND MOLDED PRODUCT FORMED OF THE SAME | TST, H1-0, H1-3 | CYP3A4 753/4885GAA 3392/4885NPC1 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.